MREO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Sentynl Therapeutics and Mereo BioPharma entered an option and license agreement for alvelestat in alpha-1 antitrypsin deficiency-associated lung diseaseAug 11, 2026
- Mereo BioPharma announces Phase 3 ORBIT and COSMIC results for setrusumab in osteogenesis imperfectaDec 29, 2025
- āshibio expands clinical pipeline with vantictumab, a first-in-class antibody for autosomal dominant osteopetrosis type 2Aug 19, 2025
- Ultragenyx and Mereo BioPharma announce UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysisJul 10, 2025